At Biotech Strategy, we’re fans of science-driven companies, and one that we’ve been keen following for over three years now is Nektar Therapeutics (NASDAQ: NKTR).
We last spoke with the “dynamic duo” Nektar’s Dr Jonathan Zalevsky (CSO) and Principal Investigator, Dr Adi Diab (MD Anderson), back at SITC17.
Since then, much noise and attention has focused on cytokines and the potential they have to improve responses with checkpoint blockade. There are plenty of sceptics out there who don’t believe they add anything in combination, while others are equally adamant that they do.
It was a pleasure to catch up with them again at ASCO 2018, and in this post we take a closer look at what the NKTR–214 data presented in Chicago does in fact tell us.
Is it hype over hope, or is it the real deal?
What did we learn about NKTR–214 at ASCO18 and how should we interpret this data from a clinical and scientific perspective?